vs

Side-by-side financial comparison of CONMED Corp (CNMD) and electroCore, Inc. (ECOR). Click either name above to swap in a different company.

CONMED Corp is the larger business by last-quarter revenue ($373.2M vs $9.2M, roughly 40.4× electroCore, Inc.). On growth, electroCore, Inc. posted the faster year-over-year revenue change (31.2% vs 7.9%). Over the past eight quarters, electroCore, Inc.'s revenue compounded faster (30.3% CAGR vs 9.3%).

The CONMED Corporation is a publicly traded American manufacturer of medical equipment and surgical devices, primarily in the orthopedic, laparoscopic and general surgery, and patient care areas. CONMED's headquarters is in Largo, Florida. Prior to July 2022, it was in Utica, New York. CONMED embraces a people-first culture that starts with a mission to support their healthcare partners and the patients they serve. They have manufacturing facilities in the United States and Mexico, offices in...

electroCore, Inc. is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD. The current chief executive officer is Daniel S. Goldberger. electroCore has one product called gammaCore, a non-invasive, commercially available product that uses vagus nerve stimulation.

CNMD vs ECOR — Head-to-Head

Bigger by revenue
CNMD
CNMD
40.4× larger
CNMD
$373.2M
$9.2M
ECOR
Growing faster (revenue YoY)
ECOR
ECOR
+23.3% gap
ECOR
31.2%
7.9%
CNMD
Faster 2-yr revenue CAGR
ECOR
ECOR
Annualised
ECOR
30.3%
9.3%
CNMD

Income Statement — Q4 2025 vs Q4 2025

Metric
CNMD
CNMD
ECOR
ECOR
Revenue
$373.2M
$9.2M
Net Profit
$-3.0M
Gross Margin
58.5%
88.4%
Operating Margin
9.8%
-31.8%
Net Margin
-32.8%
Revenue YoY
7.9%
31.2%
Net Profit YoY
6.0%
EPS (diluted)
$0.54
$-0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNMD
CNMD
ECOR
ECOR
Q4 25
$373.2M
$9.2M
Q3 25
$337.9M
$8.7M
Q2 25
$342.3M
$7.4M
Q1 25
$321.3M
$6.7M
Q4 24
$345.9M
$7.0M
Q3 24
$316.7M
$6.6M
Q2 24
$332.1M
$6.1M
Q1 24
$312.3M
$5.4M
Net Profit
CNMD
CNMD
ECOR
ECOR
Q4 25
$-3.0M
Q3 25
$2.9M
$-3.4M
Q2 25
$21.4M
$-3.7M
Q1 25
$6.0M
$-3.9M
Q4 24
$-3.2M
Q3 24
$49.0M
$-2.5M
Q2 24
$30.0M
$-2.7M
Q1 24
$19.7M
$-3.5M
Gross Margin
CNMD
CNMD
ECOR
ECOR
Q4 25
58.5%
88.4%
Q3 25
49.2%
86.0%
Q2 25
55.0%
87.3%
Q1 25
55.3%
84.9%
Q4 24
57.3%
85.9%
Q3 24
56.5%
83.8%
Q2 24
55.3%
86.3%
Q1 24
55.1%
83.7%
Operating Margin
CNMD
CNMD
ECOR
ECOR
Q4 25
9.8%
-31.8%
Q3 25
3.5%
-33.2%
Q2 25
11.1%
-47.5%
Q1 25
5.0%
-56.9%
Q4 24
15.2%
-43.6%
Q3 24
20.7%
-40.4%
Q2 24
14.2%
-42.2%
Q1 24
11.2%
-70.7%
Net Margin
CNMD
CNMD
ECOR
ECOR
Q4 25
-32.8%
Q3 25
0.8%
-39.2%
Q2 25
6.3%
-49.7%
Q1 25
1.9%
-57.4%
Q4 24
-45.8%
Q3 24
15.5%
-38.1%
Q2 24
9.0%
-43.2%
Q1 24
6.3%
-64.4%
EPS (diluted)
CNMD
CNMD
ECOR
ECOR
Q4 25
$0.54
$-0.34
Q3 25
$0.09
$-0.40
Q2 25
$0.69
$-0.44
Q1 25
$0.19
$-0.47
Q4 24
$1.09
$-0.37
Q3 24
$1.57
$-0.31
Q2 24
$0.96
$-0.38
Q1 24
$0.63
$-0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNMD
CNMD
ECOR
ECOR
Cash + ST InvestmentsLiquidity on hand
$11.6M
Total DebtLower is stronger
$834.2M
$7.8M
Stockholders' EquityBook value
$1.0B
$-1.7M
Total Assets
$2.3B
$18.7M
Debt / EquityLower = less leverage
0.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNMD
CNMD
ECOR
ECOR
Q4 25
$11.6M
Q3 25
$13.0M
Q2 25
$7.1M
Q1 25
$7.8M
Q4 24
$12.2M
Q3 24
$12.9M
Q2 24
$14.2M
Q1 24
$7.8M
Total Debt
CNMD
CNMD
ECOR
ECOR
Q4 25
$834.2M
$7.8M
Q3 25
$853.0M
$7.8M
Q2 25
$881.1M
Q1 25
$891.4M
Q4 24
$905.1M
Q3 24
$940.1M
Q2 24
$965.2M
Q1 24
$990.1M
Stockholders' Equity
CNMD
CNMD
ECOR
ECOR
Q4 25
$1.0B
$-1.7M
Q3 25
$1.0B
$-1.1M
Q2 25
$1.0B
$1.1M
Q1 25
$977.6M
$4.4M
Q4 24
$962.7M
$7.5M
Q3 24
$932.9M
$9.5M
Q2 24
$881.8M
$11.5M
Q1 24
$854.7M
$4.5M
Total Assets
CNMD
CNMD
ECOR
ECOR
Q4 25
$2.3B
$18.7M
Q3 25
$2.3B
$21.4M
Q2 25
$2.3B
$14.6M
Q1 25
$2.3B
$16.0M
Q4 24
$2.3B
$20.5M
Q3 24
$2.3B
$21.0M
Q2 24
$2.3B
$22.4M
Q1 24
$2.3B
$13.9M
Debt / Equity
CNMD
CNMD
ECOR
ECOR
Q4 25
0.81×
Q3 25
0.85×
Q2 25
0.88×
Q1 25
0.91×
Q4 24
0.94×
Q3 24
1.01×
Q2 24
1.09×
Q1 24
1.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNMD
CNMD
ECOR
ECOR
Operating Cash FlowLast quarter
$46.3M
$-1.5M
Free Cash FlowOCF − Capex
$41.2M
FCF MarginFCF / Revenue
11.0%
Capex IntensityCapex / Revenue
1.4%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$150.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNMD
CNMD
ECOR
ECOR
Q4 25
$46.3M
$-1.5M
Q3 25
$53.7M
$-1.7M
Q2 25
$29.1M
$-623.0K
Q1 25
$41.5M
$-4.4M
Q4 24
$43.3M
$-1.3M
Q3 24
$51.2M
$-1.4M
Q2 24
$43.3M
$-1.8M
Q1 24
$29.1M
$-2.6M
Free Cash Flow
CNMD
CNMD
ECOR
ECOR
Q4 25
$41.2M
Q3 25
$48.5M
$-1.7M
Q2 25
$23.4M
$-648.0K
Q1 25
$37.8M
$-4.4M
Q4 24
$39.3M
Q3 24
$47.8M
Q2 24
$39.7M
Q1 24
$27.1M
FCF Margin
CNMD
CNMD
ECOR
ECOR
Q4 25
11.0%
Q3 25
14.4%
-19.3%
Q2 25
6.8%
-8.8%
Q1 25
11.8%
-65.4%
Q4 24
11.4%
Q3 24
15.1%
Q2 24
12.0%
Q1 24
8.7%
Capex Intensity
CNMD
CNMD
ECOR
ECOR
Q4 25
1.4%
0.0%
Q3 25
1.5%
0.0%
Q2 25
1.7%
0.3%
Q1 25
1.2%
0.6%
Q4 24
1.2%
Q3 24
1.1%
Q2 24
1.1%
Q1 24
0.7%
Cash Conversion
CNMD
CNMD
ECOR
ECOR
Q4 25
Q3 25
18.78×
Q2 25
1.36×
Q1 25
6.88×
Q4 24
Q3 24
1.05×
Q2 24
1.44×
Q1 24
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CNMD
CNMD

Transferred At Point In Time$358.5M96%
Transferred Over Time$14.7M4%

ECOR
ECOR

Segment breakdown not available.

Related Comparisons